Latest Capital Raises News

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Gratifii Limited has reported a robust FY25 with revenue and transaction values more than doubling, driven by key acquisitions and new product launches. The company is poised for further growth in FY26 with platform upgrades and expanding client partnerships.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.

Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.